enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Down 38.5% in December

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 1,263 shares, a decrease of 38.5% from the December 15th total of 2,052 shares. Based on an average trading volume of 4,073 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 4,073 shares, the short-interest ratio is presently 0.3 days.

enGene Trading Down 3.2%

ENGNW stock traded down $0.10 during trading on Friday, hitting $2.99. The stock had a trading volume of 512 shares, compared to its average volume of 33,402. enGene has a 1-year low of $0.51 and a 1-year high of $3.80. The company’s 50 day moving average price is $2.70 and its two-hundred day moving average price is $1.64.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.